Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study
I'm LongbridgeAI, I can summarize articles.Bluejay Diagnostics (BJDX) announced the completion of patient enrollment in its SYMON-II sepsis study ahead of schedule, reaching 750 patients. This milestone supports the regulatory strategy for the Symphony IL-6 test. However, TipRanks' AI Analyst rates BJDX stock as Neutral due to weak financial performance and technical signals, despite positive clinical progress.
The latest announcement is out from Bluejay Diagnostics ( (BJDX) ).
On July 21, 2026, Bluejay Diagnostics announced it had completed patient enrollment in its SYMON-II multicenter clinical validation study ahead of schedule, reaching the target of 750 intensive-care sepsis patients. Conducted across leading U.S. institutions, the pivotal study evaluates the Symphony IL-6 test’s ability to help clinicians assess 28-day all-cause mortality risk in sepsis, marking a significant operational milestone for the Symphony rapid diagnostic platform.
Preliminary observations show an approximately 17% 28-day mortality rate in the cohort, providing a robust dataset to analyze the prognostic utility of IL-6 in early sepsis risk stratification. The company expects the SYMON-II results, once data cleaning and statistical analysis are completed, to form a critical component of its planned regulatory strategy for Symphony IL-6 and to advance its broader push toward regulatory submission and eventual commercialization of rapid, bedside sepsis diagnostics.
Spark’s Take on BJDX Stock
According to Spark, TipRanks’ AI Analyst, BJDX is a Neutral.
The score is held down primarily by very weak financial performance (minimal revenue, ongoing losses, and persistent cash burn). Technicals add a mildly negative signal given the stock remains below key longer-term moving averages with negative MACD. Corporate events are a modest positive due to clinical and manufacturing progress, but they do not offset the current loss-making profile and funding/dilution overhang; valuation also offers limited support given negative earnings and no dividend.
To see Spark’s full report on BJDX stock,
click here.
More about Bluejay Diagnostics
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on rapid, near-patient testing for critical care, centered on its investigational Symphony System for sepsis triage and monitoring. The company’s first product candidate, the Symphony IL-6 test for sepsis, is designed to deliver quantitative results in about 20 minutes to support earlier and more informed triage and treatment decisions in U.S. emergency and intensive care settings.
Bluejay’s technology aims to integrate into existing clinical workflows while enabling expansion to additional biomarkers and potential AI-driven decision support. The Symphony platform has not yet received U.S. Food and Drug Administration authorization, so it cannot currently be marketed as a diagnostic product in the United States, making ongoing clinical validation central to the company’s regulatory and commercialization strategy.
Average Trading Volume: 4,062,726
Technical Sentiment Signal: Sell
Current Market Cap: $1.25M
For a thorough assessment of BJDX stock, go to TipRanks’ Stock Analysis page.